Results 31 to 40 of about 35,241 (222)

Clinical Implication of Concurrent Amplification of MET and FGFR2 in Metastatic Gastric Cancer

Biomedicines, 2023
Background: c-mesenchymal epithelial transition factor receptor (c-MET) and fibroblast growth factor receptor 2 (FGFR2) amplification have been identified as factors associated with advanced stage and poor prognosis in gastric cancer (GC). While they are
Seonggyu Byeon, Jaeyun Jung, Seung Tae Kim, Kyoung-Mee Kim, Jeeyun Lee   +4 more
doaj   +1 more source

Genomic architecture of FGFR2 fusions in cholangiocarcinoma and its implication for molecular testing

British Journal of Cancer, 2022
Background Cholangiocarcinoma (CCA) is a primary malignancy of the biliary tract with a dismal prognosis. Recently, several actionable genetic aberrations were identified with significant enrichment in intrahepatic CCA, including FGFR2 gene fusions with ...
O. Neumann, T. Burn, M. Allgäuer, M. Ball, M. Kirchner, T. Albrecht, A. Volckmar, Susanne Beck, V. Endris, H. Goldschmid, U. Lehmann, H. Şeker-Cin, S. Uhrig, S. Roessler, J. Budczies, S. Fröhling, T. Longerich, A. Wagner, A. Vogel, P. Schirmacher, A. Stenzinger, D. Kazdal   +21 more
semanticscholar   +1 more source

Neonatal loss of FGFR2 in astroglial cells affects locomotion, sociability, working memory, and glia-neuron interactions in mice

Translational Psychiatry, 2023
Fibroblast growth factor receptor 2 (FGFR2) is almost exclusively expressed in glial cells in postnatal mouse brain, but its impact in glia for brain behavioral functioning is poorly understood.
Hanna E. Stevens, Soraya Scuderi, Sarah C. Collica, Simone Tomasi, Tamas L. Horvath, Flora M. Vaccarino   +5 more
doaj   +1 more source

Cancer Mutations in FGFR2 Prevent a Negative Feedback Loop Mediated by the ERK1/2 Pathway

Cells, 2019
Tight regulation of signaling from receptor tyrosine kinases is required for normal cellular functions and uncontrolled signaling can lead to cancer. Fibroblast growth factor receptor 2 (FGFR2) is a receptor tyrosine kinase that induces proliferation and
Patrycja Szybowska, Michal Kostas, Jørgen Wesche, Antoni Wiedlocha, Ellen Margrethe Haugsten   +4 more
doaj   +1 more source

FGFR2 amplification in colorectal adenocarcinoma [PDF]

Molecular Case Studies, 2017
FGFR2 is recurrently amplified in 5% of gastric cancers and 1%–4% of breast cancers; however, this molecular alteration has never been reported in a primary colorectal cancer specimen. Preclinical studies indicate that several FGFR tyrosine-kinase inhibitors (TKIs), such as AZD4547, have in vitro activity against the FGFR2-amplified colorectal cell ...
Carter, Jamal H, Cottrell, Catherine E, McNulty, Samantha N, Vigh-Conrad, Katinka A, Lamp, Stephen, Heusel, Jonathan W, Duncavage, Eric J   +6 more
openaire   +3 more sources

Deletion of fibroblast growth factor receptor 2 from the peri-wolffian duct stroma leads to ureteric induction abnormalities and vesicoureteral reflux. [PDF]

PLoS ONE, 2013
Pax3cre-mediated deletion of fibroblast growth factor receptor 2 (Fgfr2) broadly in renal and urinary tract mesenchyme led to ureteric bud (UB) induction defects and vesicoureteral reflux (VUR), although the mechanisms were unclear. Here, we investigated
Kenneth A Walker, Sunder Sims-Lucas, Valeria E Di Giovanni, Caitlin Schaefer, Whitney M Sunseri, Tatiana Novitskaya, Mark P de Caestecker, Feng Chen, Carlton M Bates   +8 more
doaj   +1 more source

FGFR2 Extracellular Domain In-Frame Deletions are Therapeutically Targetable Genomic Alterations that Function as Oncogenic Drivers in Cholangiocarcinoma.

Cancer Discovery, 2021
We conducted next generation DNA sequencing on 335 biliary tract cancers and characterized the genomic landscape by anatomic site within the biliary tree.
J. Cleary, Srivatsan Raghavan, Qibiao Wu, Yvonne Y. Li, Liam F. Spurr, H. Gupta, D. Rubinson, Isobel J. Fetter, J. Hornick, J. Nowak, G. Siravegna, L. Goyal, Lei Shi, L. Brais, M. Loftus, A. Shinagare, T. Abrams, T. Clancy, Jiping Wang, Anuj K. Patel, F. Brichory, Anne Vaslin Chessex, R. Sullivan, Rachel B. Keller, Sarah L. Denning, E. Hill, G. Shapiro, Anna Pokorska-Bocci, C. Zanna, K. Ng, D. Schrag, P. Janne, W. Hahn, A. Cherniack, R. Corcoran, M. Meyerson, Antoine Daina, V. Zoete, N. Bardeesy, B. Wolpin   +39 more
semanticscholar   +1 more source

FDFT1/FGFR2 rearrangement: A newly identified anlotinib-sensitive FGFR2 variant in cholangiocarcinoma

Cancer Treatment and Research Communications, 2022
According to previous reports,10-16% of patients with clinically advanced cholangiocarcinoma develop FGFR2 fusions or rearrangements. Treatment with FGFR2-specific inhibitors (tyrosine kinase inhibitors, TKIs) has proven effective for patients with cholangiocarcinoma.
Chunye Huang, Qin Wen, Jingyi Chen, Hongguang Zhong, Xiaojun Xiang, Jianping Xiong, Jun Deng   +6 more
openaire   +3 more sources

Tripod-shaped Syndactyly in Apert Syndrome with FGFR2 p.P253R Mutation

Indian Journal of Plastic Surgery, 2021
Apert syndrome is a rare acrocephalosyndactyly (craniosynostosis) syndrome characterized by craniofacial dysmorphism and syndactyly of the hands and feet. It is caused by FGFR2 mutations and inherited in an autosomal dominant manner.
Chandra Bhan Singh, Biswajit Mishra, Rashmi Patel, Ashok Kumar, Akhtar Ali   +4 more
doaj   +1 more source

Clinical Features of Apert Syndrome in Infancy: A rare case in Indonesia

Scripta Score Scientific Medical Journal, 2021
Background: Apert syndrome is characterized by several malformations of cranial-facial and syndactyly. The incidence of Apert syndrome was reported at approximately 1 per 65,000 live births, globally.
Muhammad Pradhika Mapindra, Muhammad Pradhiki Mahindra   +1 more
doaj   +1 more source